ARTICLE | Clinical News
Betalutin: Ph I LYMRIT 37-05 started
March 21, 2017 9:31 PM UTC
Nordic Nanovector began the open-label, dose-escalation, international Phase I LYMRIT 37-05 trial to evaluate injections of Betalutin in up to 24 patients who are ineligible for an autologous stem cel...
BCIQ Company Profiles
BCIQ Target Profiles